These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 10367664)
1. Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use. Klingbeil C; Hsu DH Toxicol Pathol; 1999; 27(1):1-3. PubMed ID: 10367664 [TBL] [Abstract][Full Text] [Related]
2. In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. Shi JD; Bullock C; Hall WC; Wescott V; Wang H; Levitt DJ; Klingbeil CK Leuk Lymphoma; 2002 Jun; 43(6):1303-12. PubMed ID: 12153000 [TBL] [Abstract][Full Text] [Related]
3. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees. Hsu DH; Shi JD; Homola M; Rowell TJ; Moran J; Levitt D; Druilhet B; Chinn J; Bullock C; Klingbeil C Transplantation; 1999 Aug; 68(4):545-54. PubMed ID: 10480415 [TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical safety of monoclonal antibodies. Tabrizi MA; Roskos LK Drug Discov Today; 2007 Jul; 12(13-14):540-7. PubMed ID: 17631248 [TBL] [Abstract][Full Text] [Related]
5. Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Bugelski PJ; Herzyk DJ; Rehm S; Harmsen AG; Gore EV; Williams DM; Maleeff BE; Badger AM; Truneh A; O'Brien SR; Macia RA; Wier PJ; Morgan DG; Hart TK Hum Exp Toxicol; 2000 Apr; 19(4):230-43. PubMed ID: 10918514 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Clarke J; Leach W; Pippig S; Joshi A; Wu B; House R; Beyer J Regul Toxicol Pharmacol; 2004 Dec; 40(3):219-26. PubMed ID: 15546677 [TBL] [Abstract][Full Text] [Related]
7. Studies on the use of nonhuman primates to determine the DR status of the human hematopoietic stem cell. Winton EF; Colenda KW; McClure HM; Chan WC; Gordon DS Exp Hematol; 1985 Oct; 13(9):869-73. PubMed ID: 3862599 [TBL] [Abstract][Full Text] [Related]
8. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. Werther WA; Gonzalez TN; O'Connor SJ; McCabe S; Chan B; Hotaling T; Champe M; Fox JA; Jardieu PM; Berman PW; Presta LG J Immunol; 1996 Dec; 157(11):4986-95. PubMed ID: 8943405 [TBL] [Abstract][Full Text] [Related]
9. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells. Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559 [TBL] [Abstract][Full Text] [Related]
10. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Jawa V; Cousens LP; Awwad M; Wakshull E; Kropshofer H; De Groot AS Clin Immunol; 2013 Dec; 149(3):534-55. PubMed ID: 24263283 [TBL] [Abstract][Full Text] [Related]
11. Drug Development of Therapeutic Monoclonal Antibodies. Mould DR; Meibohm B BioDrugs; 2016 Aug; 30(4):275-93. PubMed ID: 27342605 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates. Fishwild DM; Hudson DV; Deshpande U; Kung AH Clin Immunol; 1999 Aug; 92(2):138-52. PubMed ID: 10444358 [TBL] [Abstract][Full Text] [Related]
13. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Li B; Wang H; Dai J; Ji J; Qian W; Zhang D; Hou S; Guo Y Immunology; 2005 Dec; 116(4):487-98. PubMed ID: 16313362 [TBL] [Abstract][Full Text] [Related]
14. The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment. Lansita JA; Mounho-Zamora B Curr Pain Headache Rep; 2015; 19(2):2. PubMed ID: 25681157 [TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. van Meer PJ; Kooijman M; Brinks V; Gispen-de Wied CC; Silva-Lima B; Moors EH; Schellekens H MAbs; 2013; 5(5):810-6. PubMed ID: 23924803 [TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacokinetics and safety of Sym004: a synergistic antibody mixture directed against epidermal growth factor receptor. Skartved NJ; Jacobsen HJ; Pedersen MW; Jensen PF; Sen JW; Jørgensen TK; Hey A; Kragh M Clin Cancer Res; 2011 Sep; 17(18):5962-72. PubMed ID: 21825041 [TBL] [Abstract][Full Text] [Related]
17. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. Robak T; Robak E BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841 [TBL] [Abstract][Full Text] [Related]
18. The importance of non-human primates for preclinical testing of immunosuppressive monoclonal antibodies. Jonker M Semin Immunol; 1990 Nov; 2(6):427-36. PubMed ID: 2104280 [TBL] [Abstract][Full Text] [Related]
19. Characterization of murine anti-human Fab antibodies for use in an immunoassay for generic quantification of human Fab fragments in non-human serum samples including cynomolgus monkey samples. Stubenrauch K; Wessels U; Essig U; Kowalewsky F; Vogel R; Heinrich J J Pharm Biomed Anal; 2013 Jan; 72():208-15. PubMed ID: 23017233 [TBL] [Abstract][Full Text] [Related]
20. New monoclonal antibodies in renal transplantation. Vincenti F Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]